Marc Humbert • Oleg V. Evgenov •
Johannes-Peter Stasch
Editors

2013

Over the past decade, we have witnessed major advancements in the understanding of the molecular mechanisms and pathophysiology of pulmonary hypertension (PH) that occurred in parallel with the discovery and development of new therapies. Pharmacological agents that modulate the main pathophysiological pathways of pulmonary arterial hypertension, including endothelin-1, nitric oxide, and prostacyclin, have changed the course of this devastating disease by relieving symptoms and improving and prolonging patients’ lives.